NCT06088784View on ClinicalTrials.gov

A Study Assessing the Safety of Oral ATH-399A in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

September 19, 2023

Primary Completion Date

April 24, 2024

Study Completion Date

April 24, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

ATH-399A

Orally administered drug in capsule form.

DRUG

Placebo

Orally administered drug in capsule form.

Trial Locations (1)

QC G1P 0A2

Syneos Quebec Canada, Québec

Sponsors
All Listed Sponsors
collaborator

NurrOn Pharmaceuticals, Inc.

INDUSTRY

lead

HanAll BioPharma Co., Ltd.

INDUSTRY

NCT06088784 - A Study Assessing the Safety of Oral ATH-399A in Healthy Adult Participants | Biotech Hunter | Biotech Hunter